Zacks: Brokerages Anticipate bluebird bio Inc (BLUE) Will Announce Earnings of -$2.88 Per Share

Share on StockTwits

Equities research analysts forecast that bluebird bio Inc (NASDAQ:BLUE) will post ($2.88) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have provided estimates for bluebird bio’s earnings. The lowest EPS estimate is ($3.28) and the highest is ($2.42). bluebird bio posted earnings of ($1.73) per share in the same quarter last year, which indicates a negative year over year growth rate of 66.5%. The firm is scheduled to report its next quarterly earnings report on Wednesday, November 7th.

On average, analysts expect that bluebird bio will report full-year earnings of ($10.85) per share for the current financial year, with EPS estimates ranging from ($11.52) to ($9.39). For the next year, analysts anticipate that the company will report earnings of ($11.76) per share, with EPS estimates ranging from ($13.79) to ($10.00). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover bluebird bio.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($2.91) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.30) by ($0.61). bluebird bio had a negative net margin of 1,281.01% and a negative return on equity of 31.57%. The firm had revenue of $7.80 million for the quarter, compared to analysts’ expectations of $10.68 million. During the same period last year, the company posted ($1.73) earnings per share. The business’s revenue for the quarter was down 53.3% compared to the same quarter last year.

Several analysts recently commented on BLUE shares. William Blair reissued a “buy” rating on shares of bluebird bio in a research report on Wednesday, September 5th. Gabelli started coverage on shares of bluebird bio in a research report on Thursday, July 12th. They set a “buy” rating and a $239.00 price objective on the stock. Cowen reissued a “buy” rating on shares of bluebird bio in a research report on Monday, August 6th. SunTrust Banks reissued a “buy” rating and set a $223.00 price objective on shares of bluebird bio in a research report on Friday, August 3rd. Finally, BMO Capital Markets reissued a “buy” rating and set a $208.00 price objective on shares of bluebird bio in a research report on Friday, August 3rd. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and fifteen have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $212.21.

Shares of BLUE stock opened at $126.77 on Monday. bluebird bio has a one year low of $120.02 and a one year high of $236.17. The stock has a market cap of $7.91 billion, a P/E ratio of -16.44 and a beta of 1.89.

In other news, insider Alison Cecily Finger sold 259 shares of the firm’s stock in a transaction dated Monday, August 20th. The shares were sold at an average price of $158.07, for a total transaction of $40,940.13. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Philip D. Gregory sold 1,800 shares of the firm’s stock in a transaction dated Monday, August 6th. The shares were sold at an average price of $156.61, for a total transaction of $281,898.00. Following the sale, the insider now directly owns 33,471 shares in the company, valued at approximately $5,241,893.31. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 62,859 shares of company stock worth $10,029,606. Insiders own 3.00% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in BLUE. Tower Research Capital LLC TRC purchased a new position in shares of bluebird bio in the second quarter worth approximately $201,000. XR Securities LLC purchased a new position in shares of bluebird bio in the second quarter worth approximately $212,000. Laurel Wealth Advisors Inc. purchased a new position in shares of bluebird bio in the first quarter worth approximately $215,000. Atria Investments LLC purchased a new position in shares of bluebird bio in the third quarter worth approximately $216,000. Finally, First Republic Investment Management Inc. purchased a new position in shares of bluebird bio in the second quarter worth approximately $234,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Further Reading: Put Option

Get a free copy of the Zacks research report on bluebird bio (BLUE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply